Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743543 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of SPG Block for PTSD
A Early Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05743543 is a Early Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 6 participants.
The verdict
NCT05743543, a Early Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.
Interventions
- OTHER Sphenopalatine ganglion block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2023-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743543
The ClinicalTrials.gov registry entry for NCT05743543 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sphenopalatine ganglion block is the first listed.
NCT05743543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05743543 about?
NCT05743543 is a clinical study titled "A Pilot Study of SPG Block for PTSD". Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.
What is the current status of trial NCT05743543?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-05-28. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT05743543?
The interventions under investigation include: Sphenopalatine ganglion block (OTHER).
Who is sponsoring clinical trial NCT05743543?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.